Copyright
©The Author(s) 2022.
World J Gastroenterol. Feb 14, 2022; 28(6): 665-674
Published online Feb 14, 2022. doi: 10.3748/wjg.v28.i6.665
Published online Feb 14, 2022. doi: 10.3748/wjg.v28.i6.665
Table 2 Comparison of baseline characteristics of patients with and without hepatocellular carcinoma
| Patients with HCC | Patients without HCC | P value | |
| Age (yr) mean ± SE | 57.8 ± 2.3 | 44.5 ± 0.5 | < 0.001 |
| Male gender, n (%) | 24 (92.3) | 448 (62.6) | 0.004 |
| Cirrhosis, n (%) | 16 (61.5) | 145 (20.3) | < 0.001 |
| Diabetes mellitus, n (%) | 8 (32) | 108(15.1) | 0.043 |
| Antiviral treatment (ETV/TDF), n (%) | 10 (38.5)/16 (61.5) | 230 (32.1)/486 (67.9) | 0.642 |
| Laboratory (mean ± SE) | |||
| HBeAg positivity, n (%) | 6 (23.1) | 165 (23.0) | 1.000 |
| ALT (IU/L) | 92.9 ± 25.7 | 98.3 ± 5.7 | 0.856 |
| Albumin (g/dL) | 3.9 ± 0.1 | 4.1 ± 0.0 | 0.014 |
| Total bilirubin (mg/dL) | 0.9 ± 0.1 | 1.0 ± 0.1 | 0.709 |
| AFP (ng/mL) | 23.3 ± 9.6 | 5.2 ± 0.4 | < 0.001 |
| INR | 1.1 ± 0.0 | 1.1 ± 0.0 | 0.143 |
| Platelet (10³/mL) | 128.8 ± 8.6 | 203.5 ± 2.5 | < 0.001 |
| HBV-DNA (log IU/mL) | 5.4 ± 0.3 | 5.5 ± 0.1 | 0.859 |
- Citation: Gokcen P, Guzelbulut F, Adali G, Degirmenci Salturk AG, Ozturk O, Bahadir O, Kanatsiz E, Kiyak M, Ozdil K, Doganay HL. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment. World J Gastroenterol 2022; 28(6): 665-674
- URL: https://www.wjgnet.com/1007-9327/full/v28/i6/665.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i6.665